Latest news with #LRMR
San Francisco Chronicle
6 days ago
- Business
- San Francisco Chronicle
Larimar: Q2 Earnings Snapshot
BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Thursday reported a loss of $26.2 million in its second quarter. The Bala Cynwyd, Pennsylvania-based company said it had a loss of 41 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 47 cents per share. _____
Yahoo
21-05-2025
- Business
- Yahoo
Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential
We recently published an article titled . Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article. Wall Street analysts believe LRMR has a 957% upside potential over the next 12 months. Closeup shot of a scientist in a lab coat examining a microscope for breakthroughs in biotechnology. Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a biotechnology company focused on developing innovative treatments for rare genetic disorders. Among its pioneering efforts is the development of Nomlabofusp (CTI-1601), a therapeutic candidate specifically designed to address Friedreich's ataxia (FA). This rare and progressive genetic disorder stems from insufficient levels of frataxin, a mitochondrial protein essential for proper cellular function. By delivering frataxin to affected cells, Nomlabofusp aims to target the core deficit of FA, offering hope for improved cellular health and a potential slowing of disease progression. Central to Larimar's scientific approach is its proprietary intracellular delivery platform. This technology enables therapeutic molecules to cross cell membranes effectively, opening new possibilities for addressing other rare diseases marked by similar deficiencies or intracellular dysfunctions. The company continues to explore and expand its pipeline, leveraging this platform to address unmet needs in the realm of rare diseases. This forward-thinking strategy positions Larimar as a leader in developing transformative therapies in the biotechnology sector. In December of last year, the company disclosed that two patients experienced serious adverse events related to its experimental therapy, nomlabofusp, a treatment for Friedreich's ataxia (FA. This lead to a decline in the company's share price by 30% in intra-day trading. Larimar Therapeutics, however, maintains a strong financial foundation. The company's Q1 2025 earnings report highlighted its solid financial position with $157.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This financial stability provides the resources necessary to sustain research and development activities and bolster commercialization efforts. Furthermore, Larimar projects its cash runway to extend well into the second quarter of 2026, ensuring continued progress in its clinical programs. Analysts have taken note of Larimar's promising trajectory, expressing confidence in the company's potential for growth. With an upside of 957.52%, the stock's estimated twelve-month price projection stands at $20.04, reflecting optimism about the potential impact of the company's groundbreaking work. Through its innovative technologies, strategic focus, and financial resilience, Larimar Therapeutics is advancing solutions that may redefine the treatment of rare diseases for patients worldwide. Overall, Larimar Therapeutics, Inc. (NASDAQ:LRMR) ranks 2nd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of LRMR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LRMR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential
We recently published an article titled . Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article. Wall Street analysts believe LRMR has a 957% upside potential over the next 12 months. Closeup shot of a scientist in a lab coat examining a microscope for breakthroughs in biotechnology. Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a biotechnology company focused on developing innovative treatments for rare genetic disorders. Among its pioneering efforts is the development of Nomlabofusp (CTI-1601), a therapeutic candidate specifically designed to address Friedreich's ataxia (FA). This rare and progressive genetic disorder stems from insufficient levels of frataxin, a mitochondrial protein essential for proper cellular function. By delivering frataxin to affected cells, Nomlabofusp aims to target the core deficit of FA, offering hope for improved cellular health and a potential slowing of disease progression. Central to Larimar's scientific approach is its proprietary intracellular delivery platform. This technology enables therapeutic molecules to cross cell membranes effectively, opening new possibilities for addressing other rare diseases marked by similar deficiencies or intracellular dysfunctions. The company continues to explore and expand its pipeline, leveraging this platform to address unmet needs in the realm of rare diseases. This forward-thinking strategy positions Larimar as a leader in developing transformative therapies in the biotechnology sector. In December of last year, the company disclosed that two patients experienced serious adverse events related to its experimental therapy, nomlabofusp, a treatment for Friedreich's ataxia (FA. This lead to a decline in the company's share price by 30% in intra-day trading. Larimar Therapeutics, however, maintains a strong financial foundation. The company's Q1 2025 earnings report highlighted its solid financial position with $157.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This financial stability provides the resources necessary to sustain research and development activities and bolster commercialization efforts. Furthermore, Larimar projects its cash runway to extend well into the second quarter of 2026, ensuring continued progress in its clinical programs. Analysts have taken note of Larimar's promising trajectory, expressing confidence in the company's potential for growth. With an upside of 957.52%, the stock's estimated twelve-month price projection stands at $20.04, reflecting optimism about the potential impact of the company's groundbreaking work. Through its innovative technologies, strategic focus, and financial resilience, Larimar Therapeutics is advancing solutions that may redefine the treatment of rare diseases for patients worldwide. Overall, Larimar Therapeutics, Inc. (NASDAQ:LRMR) ranks 2nd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of LRMR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LRMR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
30-04-2025
- Business
- Yahoo
Larimar: Q1 Earnings Snapshot
BALA CYNWYD, Pa. (AP) — BALA CYNWYD, Pa. (AP) — Larimar Therapeutics, Inc. (LRMR) on Wednesday reported a loss of $29.3 million in its first quarter. The Bala Cynwyd, Pennsylvania-based company said it had a loss of 46 cents per share. The results fell short of Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on LRMR at Sign in to access your portfolio
